Analysts Anticipate Cardiovascular Systems, Inc. (CSII) to Announce -$0.04 EPS
Brokerages predict that Cardiovascular Systems, Inc. (NASDAQ:CSII) will post earnings of ($0.04) per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Cardiovascular Systems’ earnings. The highest EPS estimate is ($0.02) and the lowest is ($0.05). Cardiovascular Systems posted earnings of $0.03 per share in the same quarter last year, which suggests a negative year over year growth rate of 233.3%. The business is scheduled to report its next quarterly earnings results on Wednesday, January 24th.
On average, analysts expect that Cardiovascular Systems will report full year earnings of ($0.05) per share for the current fiscal year, with EPS estimates ranging from ($0.08) to ($0.02). For the next financial year, analysts expect that the firm will post earnings of $0.14 per share, with EPS estimates ranging from $0.11 to $0.16. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for Cardiovascular Systems.
Cardiovascular Systems (NASDAQ:CSII) last announced its earnings results on Wednesday, October 25th. The medical device company reported ($0.06) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.08) by $0.02. The business had revenue of $49.70 million during the quarter, compared to analysts’ expectations of $51.00 million. Cardiovascular Systems had a negative net margin of 0.93% and a positive return on equity of 0.74%. The firm’s revenue was down .2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.06) earnings per share.
Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA boosted its stake in Cardiovascular Systems by 160.7% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 5,135 shares of the medical device company’s stock worth $166,000 after purchasing an additional 3,165 shares in the last quarter. BlueCrest Capital Management Ltd purchased a new position in Cardiovascular Systems during the 2nd quarter worth approximately $204,000. Legal & General Group Plc raised its position in Cardiovascular Systems by 2.9% during the 2nd quarter. Legal & General Group Plc now owns 7,763 shares of the medical device company’s stock worth $249,000 after buying an additional 216 shares during the last quarter. Advisor Group Inc. raised its position in Cardiovascular Systems by 0.4% during the 2nd quarter. Advisor Group Inc. now owns 8,165 shares of the medical device company’s stock worth $263,000 after buying an additional 35 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Cardiovascular Systems by 34.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 8,239 shares of the medical device company’s stock worth $265,000 after buying an additional 2,115 shares during the last quarter. Institutional investors own 75.05% of the company’s stock.
Shares of Cardiovascular Systems (NASDAQ CSII) traded up $0.16 during trading hours on Thursday, hitting $23.93. 117,400 shares of the company were exchanged, compared to its average volume of 269,888. The company has a current ratio of 4.30, a quick ratio of 3.83 and a debt-to-equity ratio of 0.18. Cardiovascular Systems has a 12-month low of $23.00 and a 12-month high of $33.11. The company has a market capitalization of $811.07, a price-to-earnings ratio of 1,188.50 and a beta of 2.52.
About Cardiovascular Systems
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cardiovascular Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.